Pfizer (PFE) Short-term Investments (2009 - 2026)

Pfizer has disclosed Short-term Investments across 18 years of filings, most recently posting $11.4 billion for Q1 2026.

• In Q1 2026, Short-term Investments fell 28.42% year-over-year to $11.4 billion; the TTM figure through Mar 2026 stood at $11.4 billion (down 28.42% YoY), while the FY2025 annual figure was $12.5 billion, down 35.92% from the prior year.
• Short-term Investments declined to $11.4 billion in Q1 2026, from $12.5 billion in the prior quarter.
• Over the last five years, Short-term Investments for PFE reached as high as $42.2 billion in Q3 2023 and fell as low as $6.0 billion in Q2 2024.
• The 5-year median for Short-term Investments is $15.9 billion (2025), against an average of $19.5 billion.
• The widest YoY moves for Short-term Investments: up 97.56% in 2024, down 85.65% in 2024.
• A 5-year view of Short-term Investments shows it stood at $22.3 billion in 2022, then sank by 55.92% to $9.8 billion in 2023, then jumped by 97.56% to $19.4 billion in 2024, then plunged by 35.92% to $12.5 billion in 2025, then slipped by 8.69% to $11.4 billion in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $11.4 billion, $12.5 billion, and $13.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.